Forbes magazine releases its “30 Under 30” list at the beginning of each year, highlighting 30 outstanding young leaders under the age of 30 across various industries worldwide. This year’s competition has been particularly fierce, with judges selecting 600 young individuals from 20 different industries out of 15,000 nominees.

In the healthcare industry, there are thousands of candidates under the age of 30—researchers, entrepreneurs, healthcare decision-makers, and more—who are shaping the forefront of medical advancements in the United States and around the world. Forbes has carefully selected from this pool to identify the following top 30 most talented, promising, and influential young healthcare professionals.

Last year, more than 10,000 people died because they were unable to convey accurate information immediately after dialing 911 for emergency assistance. Many individuals are too panicked in critical situations to clearly state their location, and some even misreport their phone numbers. But what if smartphones could handle this for you? This is the foundational concept behind Haven, an app developed by RapidSOS. With a single tap, users can instantly transmit their precise location to 911 dispatchers.

“Various technologies have ushered us into the modern era, yet the 911 emergency response process remains as outdated as it was in the 1960s,” said Michael Martin, co-founder of RapidSOS. RapidSOS has raised $14 million in funding and integrated its system with 911 call centers across China. Currently, the technology is used only 25,000 times per month, accounting for just 0.2% of all 911 calls, indicating substantial room for growth. “In the future, Haven will come pre-installed on all wearables, vehicles, and mobile devices, allowing instant access whenever you need it.”

After being diagnosed with cancer, Nick Valilis found it extremely difficult to remember to take his medication on schedule. Consequently, he teamed up with several of his college roommates to co-found TowerView Health, a company dedicated to manufacturing and selling customized smart pillboxes.

In the United States, the average wait time for a dermatology appointment is currently 29 days. To eliminate this delay, Elisabeth Asai founded 3Derm, leveraging telemedicine to streamline access to care. Primary care physicians can capture diagnostic-quality images of patients and transmit them to dermatologists for remote evaluation; if necessary, an in-person follow-up consultation can be arranged. As a result, Medicaid-enrolled patients served by 3Derm now receive medical services 20 times faster than before.

Adam Behrens is working in the laboratory of Robert Langer, a renowned serial entrepreneur in biotechnology. He is also leading two projects focused on bacteria in developing countries: one aims to develop vaccines that do not require refrigeration, and the other seeks to advance point-of-care diagnostic technologies for infectious diseases. Behrens is currently researching surgical sealants.

Wellframe’s business involves selling a mobile app to health insurance companies that helps patients manage complex conditions, such as comorbid diabetes and cancer. The app also enables insurers to maintain close engagement with their members. Investors including Draper Fisher Jurvetson and Jonathan Bush, CEO of AthenaHealth, have invested $10 million in Wellframe.

Clostridioides difficile is a lethal pathogen that is typically resistant to antibiotics, with infections generally occurring after beneficial gut microbiota are eradicated by antimicrobial agents. A paper published by Carrie Cowardin in Nature Microbiology, a subsidiary journal of Nature, further demonstrates that it is not only antibiotics that kill beneficial bacteria; a virulent strain of C. difficile also releases a toxin that kills commensal gut microbes.

After his father passed away from a brain tumor, Matthew De Silva raised $7 million to help patients find the right oncology treatments. Today, many cancer specialists send tumor samples to De Silva’s company, Notable Labs, which tests these samples against thousands of drug combinations and returns the results to physicians within days.

Prarthna Desai left her graduate program at Harvard University to use drones in helping people in developing countries access medication support. She leads business operations at Zipline, which is working with Rwanda’s healthcare system to bring drone-based medicine delivery to the region.

Despite unprecedented advances in cancer treatment, the highest survival rates are still achieved through early diagnosis and early intervention. Unfortunately, cancer is often diagnosed only after symptoms appear, causing patients to miss the optimal window for treatment. Freenome has raised $7 million to develop a blood test capable of screening for multiple types of cancer by monitoring changes in DNA fragments over time.

He Jiang grew up in Ningxiang County, Changsha, Hunan Province, China, where there were no cars, no electricity, and no running water; he even experienced the collapse of his school during a rainstorm. During his postdoctoral tenure at Harvard, he employed a novel technique called single-virus particle tracking, using ultra-high-resolution imaging to investigate how influenza viruses interact with cells, and is currently searching for human genes with high antiviral resistance. He is now also applying this technology to neurons and white blood cells.

He Jiang recalls being bitten by a spider as a child, when his mother treated the wound with fire. One of his aspirations is to replace such outdated folk remedies with science, enabling regions lacking hospitals and medicines to gain access to quality healthcare resources sooner.

Before the age of 27, David Hysong had researched child sexual slavery in Cambodia and trained as a member of the Navy SEALs. Later, after being diagnosed with a rare form of head and neck cancer with a very low cure rate, Hysong founded Shepherd Bio to seek treatments for patients with rare cancers like himself. He stated that the company has raised $6.5 million in its angel funding round and will initiate its Series A financing shortly.

Emilia Javorsky’s graduate school mentor developed a technique for freezing and removing subcutaneous fat, which was applied to the medical aesthetics industry. Now, she is also utilizing this technology, but for disease treatment. Her company has raised $7.5 million to test a method capable of freezing fat in any part of the body, which holds potential for treating conditions such as sleep apnea and type 2 diabetes.

Lydia Kisley specializes in using cutting-edge technologies to image nanoscale chemical substances, aiming to investigate how they can be better utilized. Her research achievements include: discovering that proteins aggregate into clusters in the presence of low-concentration gold nanoparticles; deepening the understanding of drug molecule binding states and enabling scientists to identify void spaces within any nanoparticle.

Neonatal jaundice accounts for 50% of hospital readmissions among newborns worldwide and claims the lives of an average of 10 infants every hour. The standard treatment is phototherapy using specialized blue fluorescent lamps, a procedure typically available only in hospitals. NeoLight has changed this landscape by inventing a home-use phototherapy device for jaundice. Additionally, the company is developing another tool designed to treat neonatal hypothermia.

Lumbar puncture is extremely painful, and IntuiTap, with patient care in mind, aims to reduce the discomfort associated with this procedure. IntuiTap employs imaging technology, pressure sensors, and predictive analytics to streamline the process and enhance the accuracy of lumbar punctures.

Alaa Murabit, nicknamed the “Libyan Wonder Doctor” by comedian Jon Stewart, was admitted to medical school at the age of 15. In her final year of study, she turned her attention to politics and founded Voice of Libyan Women, a non-profit organization dedicated to supporting and empowering Libyan women affected by conflict. Four years later, she led research on health security issues at the United Nations, where Murabit also served as the only Senior Advisor under the age of 45.

Sudhakar Nuti’s research focuses on disparities in healthcare quality in the United States, and he has published multiple studies in the Journal of the American Medical Association. A recent finding indicates that, despite controversies surrounding the healthcare services provided by the U.S. Department of Veterans Affairs, there is no significant difference in the quality of care between Veterans Affairs hospitals and other hospitals.

Kevin O’Rourke specializes in the most common forms of colorectal cancer. In 2015, his research published in Cell demonstrated that a gene called APC, identified in mice, can drive colon cancer. Furthermore, silencing the APC gene cured colon cancer in mice, even when other oncogenes remained active. Memorial Sloan Kettering Cancer Center, where O’Rourke is affiliated, held this discovery in high regard, hailing it as one of the top findings of the year.

As the Chief Resident in Orthopedic Surgery at Harvard, Patel has published more than a dozen scientific papers in surgical journals. Now venturing into the corporate sector, his company, OrthoNinja, has developed a mobile app that facilitates seamless communication and peer consultation among physicians. In its first year of operation, the app facilitated over 200 physician consultations across China.

Ashwin Pushpala believes that the methods used in traditional preventive healthcare are “fundamentally flawed.” His company, Sano, aims to leverage sensors to support personalized medicine and has raised $18.75 million to develop sensors capable of measuring indicators such as blood glucose levels, enabling individuals to more intuitively monitor changes in their bodies.

Srilakshmi Raj began her medical research at the age of 14. Currently, as a postdoctoral fellow at Cornell University specializing in population genetics, she is investigating whether susceptibility to certain chronic diseases has varied across different ethnic groups under evolutionary selection. Her research portfolio is extensive, ranging from studies on hypertension in African patients to investigations into cold resistance among Siberian populations.

Why do people feel happy or sad? What does it truly mean to “focus attention on something”? Matthew Sacchet is investigating the neural mechanisms underlying major depressive disorder and attentional deficits, while also seeking to unravel certain mysteries of the brain, such as the principles behind training the mind through practices like meditation.

After being diagnosed at age 19 with Behçet’s disease, a rare autoimmune disorder, Emily Schlichting became a staunch advocate for ensuring that insurance companies cover medical costs for patients with chronic conditions like hers. In 2011, Schlichting testified before Congress on the Affordable Care Act, and her efforts ultimately led to her joining the U.S. Department of Health and Human Services. There, she helped facilitate the appointment of the new Commissioner of the U.S. Food and Drug Administration (FDA) and participated in negotiations surrounding the 21st Century Cures Act.

Tyler Shultz exposed the lies of a healthcare company, which became the biggest news in the industry this year. This refers to the notorious fraud scandal involving Theranos. In November, The Wall Street Journal revealed that Shultz was the secret whistleblower behind the exposé. Now he has embarked on a new research project: a tool capable of detecting cannabis concentration by measuring the levels of tetrahydrocannabinol (THC), an active ingredient in cannabis, using only a small amount of saliva.

One of the biggest challenges in the healthcare industry is the frequent need to transfer data from one system to another. Niko Skievaski’s company, Redox, has raised $4 million to develop an application that enables cross-platform access to patient data, bridging the gap between medical data and various healthcare software systems. The company has already established partnerships with more than 1,000 software vendors.

Rohan Suri’s brother suffered greatly due to a missed concussion diagnosis, which inspired him to develop more advanced concussion screening tests. Eye-tracking tests are an increasingly popular method for diagnosing concussions, but the equipment required is expensive. Therefore, this 17-year-old founded Averia to create a device that can perform eye-tracking tests using headphones and a physician’s smartphone. From last June to the present, Suri’s tool has completed 60 concussion diagnoses.

Universities can leverage federal funding to develop new drugs, so why not further advance their translation into clinical treatments? This is the core mission of the Coalition for Basic Pharmaceutical Universities. Gloria Tavera, M.D., of Case Western Reserve University, is one of the founders and currently serves as its chair. The coalition now comprises 100 chapters, with members across universities in 18 cities throughout the United States.

A large number of patients in China suffer from circulatory problems due to abnormal vascular valve function. Austin Walker’s company, Innovein, is developing an artificial valve to address this issue. Notably, Innovein is one of the few medical device startups supported by the renowned startup incubator Y Combinator. The company’s product has already passed laboratory verification and animal testing, and human trials are scheduled to begin in the coming year.

Wang co-founded KSQ Therapeutics, a company that leverages the latest gene-editing tool—CRISPR technology—to develop novel therapeutics. The drug screening technology he invented is part of his research aimed at identifying genes amenable to targeted therapies for cancer and neurodegenerative diseases.

After graduating from Harvard Medical School, Arsani William decided to enter the financial industry. He now leads healthcare investments at Farallon Capital Management, where his team currently manages approximately $2 billion in assets.